報價延遲最少15分鐘:2025/07/18 17:49 EDT
盤後時段
|
||||
|
9.2 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.02
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.61/-4.29
|
|
企業價值
1.35B
|
| 資產負債 |
|
每股賬面淨值
4.73
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 17:49 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
